Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

A synthetic control arm for refractory metastatic colorectal cancer: the no placebo initiative


This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Three-step analysis for no-placebo initiative.


  1. FDA. Placebos and Blinding in Randomized Controlled Cancer Clinical Trials for Drug and Biological Products, Guidance for Industry (2019).

  2. Grothey, A. et al. Lancet 381, 303–312 (2013).

    Article  CAS  PubMed  Google Scholar 

  3. Mayer, R. J. et al. N. Engl. J. Med. 372, 1909–1919 (2015).

    Article  PubMed  Google Scholar 

  4. Van Cutsem, E. et al. Ann. Oncol. 29, 1955–1963 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Jonker, D. J. et al. Lancet Gastroenterol. Hepatol. 3, 263–270 (2018).

    Article  PubMed  Google Scholar 

  6. Li, J. et al. JAMA 319, 2486–2496 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Xu, J. et al. J. Clin. Oncol. 36, 350–358 (2018).

    Article  CAS  PubMed  Google Scholar 

  8. Li, J. et al. Lancet Oncol. 16, 619–629 (2015).

    Article  CAS  PubMed  Google Scholar 

  9. Yoshino, T. et al. Lancet Oncol. 13, 993–1001 (2012).

    Article  CAS  PubMed  Google Scholar 

  10. Dasari, N. A. et al. Ann. Oncol. 33, S1391–S1392 (2022).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Takayuki Yoshino.

Ethics declarations

Competing interests

T.Y. reports honoraria from Bayer, Chugai, Merck Biopharma, MSD, Ono and Takeda; research funding from Taiho, Sumitomo Dainippon, Ono, Chugai, Amgen, Parexel International, MSD, Daiichi-Sankyo, Eisai, FALCO biosystems, Genomedia, Molecular Health, Nippon Boehringer Ingelheim, Pfizer, Roche Diagnostics, Sysmex and Sanofi. Q.S. reports a consulting and advisory role from Yiviva, Boehringer Ingelheim Pharmaceuticals, Regeneron Pharmaceuticals, Hoosier Cancer Research Network, Kronos Bio and Mirati Therapeutics; an honorarium and speaker role from Chugai Pharmaceutical Co. (directly to Q.S.); research funds from Celgene/BMS, Roche/Genentech, Janssen and Novartis (to Q.S.’s institution). T.M. reports honoraria from Chugai and AstraZeneca. H.B. reports a grant from Ono; honoraria from Taiho, Eli Lilly Japan and Ono. M.W. reports honoraria from Nihon Medi-Physics. T.A. reports attending advisory board meetings and receiving consulting fees from Aptitude Health, Astellas, Bristol Myers Squibb, Gilead, Gritstone Oncology, GamaMabs Pharma SA, GSK, Kaleido Oncology, Merck & Co., Seagen, Servier and Transgène; honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Bristol Myers Squibb, Gritstone Oncology, GSK, Merck & Co., Merck Serono, Pierre Fabre, Roche, Seagen and Servier; support for attending meetings and/or travel from Servier and Merck & Co.; and is President of the ARCAD Foundation. M.R. and A.G. have no competing interests to declare.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yoshino, T., Shi, Q., Misumi, T. et al. A synthetic control arm for refractory metastatic colorectal cancer: the no placebo initiative. Nat Med 29, 2389–2390 (2023).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer